NEW YORK (GenomeWeb) – San Francisco-based genetic testing company Invitae has filed a prospectus for an initial public offering of its stock for up to $86 million.

Invitae has not priced its shares nor said how many it plans to offer, but said in its Form S-1 filed with the US Securities and Exchange Commission that it plans to trade on the New York Stock Exchange under the symbol "NVTA."

JP Morgan Securities, Cowen and Company, and Leerink Partners are listed as underwriters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.